AIFM & Portfolio Manager

In July 2014, the Company adjusted its operational arrangements to ensure compliance with the Alternative Investment Fund Managers Directive, (AIFMD). Frostrow Capital was appointed as the designated Alternative Investment Fund Manager for the Company. Under a portfolio management agreement with Frostrow Capital, OrbiMed was appointed to manage the Company’s portfolio of investments.  These arrangements were put in place to ensure that the relationship between the Company, OrbiMed and Frostrow Capital LLP is compliant with the requirements of AIFMD.

OrbiMed Capital LLC

OrbiMed has many years experience of valuing companies in the pharmaceutical, biotechnology and healthcare sectors. The US-based company employs 80 experienced investment professionals. OrbiMed carries out extensive research, which involves company visits and developing an understanding of commercial prospects and development programmes for individual drugs. About 750 public healthcare companies are researched in detail and a further 1,200 private companies are tracked on global basis. OrbiMed is also the Portfolio Manager of Worldwide Healthcare Trust PLC.

For more information on OrbiMed, please see their website: www.orbimed.com

Geoffrey C. Hsu

Portfolio Manager

Find out more

×

Geoffrey C. Hsu

Geoffrey C Hsu, CFA, joined OrbiMed in 2002 as a biotechnology analyst and is a Partner at OrbiMed. Prior to joining OrbiMed, he worked as a financial analyst in the healthcare investment banking group at Lehman Brothers. Mr Hsu received his AB degree summa cum laude from Harvard University and holds an MBA from Harvard Business School. Prior to business school, he spent two years studying medicine at Harvard Medical School.

Josh Golomb

Portfolio Manager

Find out more

×

Josh Golomb

Joshua Golomb is a Partner on the Public Equity team. Mr. Golomb has over 17 years of experience on the buyside covering biotechnology and pharmaceutical stocks. Prior to joining OrbiMed, Mr. Golomb was an Analyst at HealthCor covering biotechnology and pharmaceuticals. Previously, he covered the same sectors as a buyside Analyst at Millennium, Citadel, Diamondback and ProMed. Mr. Golomb holds a B.S. in Operations Research with a concentration in Engineering Management Systems from the Fu Foundation School of Engineering and Applied Science at Columbia University.